Tarsus Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 3, 2026, disclosing financial and operational details for the third quarter of fiscal 2026.

Key Highlights

  • Single commercial product: The company disclosed it is a commercial-stage biopharmaceutical company with one product approved for commercial sale, XDEMVY (lotilaner ophthalmic solution) 0.25%, which received U.S. regulatory approval in July 2023 and launched commercially in August 2023.
  • Recent positive cash flow: According to the filing, the company "recently generated positive cash flows from operations" but has "continued to incur losses and historically generated negative cash flows from operations since our inception."
  • Shares outstanding: As of October 29, 2026, there were 49,305,552 shares of common stock outstanding, par value $0.0001 per share.
  • Pipeline candidates disclosed: The filing identified active product candidates including TP-04 for potential treatment of ocular rosacea, TP-05 for potential Lyme disease prophylaxis and community malaria reduction, IRX-101 as a potential ocular antiseptic, and ALK-001 for potential treatment of Stargardt disease.
  • Recent acquisitions: The filing stated the company "recently completed the acquisitions of iRenix and Alkeus" and noted these transactions "have resulted in, and future transactions could result in, substantial contingent milestone and royalty payment obligations, dilution" to existing stockholders.
  • Large accelerated filer: The company is classified as a large accelerated filer as of the filing date.

XDEMVY Commercialization and Pipeline Development at Tarsus Pharmaceuticals

According to the Form 10-Q filed with the SEC for the quarterly period ended September 30, 2026, Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) reported continued commercialization of XDEMVY, its sole approved product, while advancing a pipeline of candidates across multiple therapeutic areas. The company disclosed that although it has recently achieved positive operating cash flows, it anticipates it "could continue to incur significant expenses and potential losses in future periods."

The filing disclosed that the development and commercialization of XDEMVY and certain pipeline candidates, including TP-04 and TP-05, depend on intellectual property in-licensed from Elanco Tiergesundheit AG, while IRX-101 and ALK-001 rely on licenses from other third parties. The company cautioned that a breach or termination of those agreements "could lose license rights that are important to our business." The filing also noted reliance on third-party contract manufacturers and, in some cases, single-source suppliers, which the company said "increases the risk that we will not have sufficient quantities of XDEMVY" or related components at acceptable costs.

Among the key risks the company disclosed, it noted that the market opportunity for XDEMVY in Demodex blepharitis "may be smaller than we estimate, possibly materially," and that unfavorable global and geopolitical economic conditions, including tariffs, "could adversely affect our business, financial condition or results of operations." The filing also addressed the recently completed acquisitions of iRenix and Alkeus, flagging integration risk and contingent financial obligations.

What Was Disclosed

Tarsus Pharmaceuticals filed its Q3 2026 quarterly report describing the ongoing commercialization of XDEMVY, risk factors related to its pipeline, third-party manufacturing dependencies, in-licensing arrangements, and the recent acquisitions of iRenix and Alkeus, with 49,305,552 shares outstanding as of October 29, 2026.